Daiichi Sankyo Europe GmbH

European News

  • Oncology
    • Locked
    Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO Virtual Meeting
  • Oncology
    • Locked
    Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer
  • Cardio
    • Locked
    New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation
  • Oncology
    • Locked
    ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
  • Oncology
    • Locked
    Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCT
  • Oncology
    • Locked
    Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
  • Oncology
    • Locked
    DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer
  • Oncology
    • Locked
    DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung Cancer
  • Oncology
    • Locked
    Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma
  • Company
    Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
back to top

User login

Enter your username and password here in order to log in on the website

Password forgotten? Register
Password forgotten? Register Help
This Website uses cookies which are essential for providing our services and core website functionality. In addition, if you click on "I AGREE", we will further use analytical and advertising cookies to analyse your use of our Website so that we can improve its functionality and display content tailored according to your interests and preferences, including on third party websites. We use Google Analytics and its tracking and remarketing features connected with Google Ads. This means that cookies on your device will be placed and accessed by Google LLC in the USA enabling us and third parties participating in the Google advertising network to conduct conversion tracking and remarketing activities across different websites and devices. By accepting analytical and advertising cookies you consent to the respective processing and sharing of your personal data with Google LLC. You can withdraw your consent and change your cookie preferences at any time by using our Cookie preferences tool . To refuse consent and continue without analytical and advertising cookies, please click on "I DO NOT AGREE". For more information see our Privacy policy .